Harris D N, Hedberg A, Phillips M B, Michel I M, Goldenberg H J, Liu E C
Department of Pharmacology, Squibb Institute for Medical Research, Princeton, New Jersey 08543-4000.
Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:482-6.
Small structural changes in a series of 7-oxabicyclo[2.2.1]heptyl acids have produced four types of agents that modify the actions of TXA2 and PG. We showed that SQ 26,655 is a TXA2 receptor agonist, SQ 28,668 and SQ 29,548 are TXA2 receptor antagonists, SQ 28,852 is a CO inhibitor, and SQ 27,986 is a PGI2/PGD2 agonist. SQ 30,077 bound reversibly with high affinity to one site in human platelet membranes. The specific binding of SQ 30,077 is competitively inhibited by the identified TXA2 receptor agonists and antagonists with an order of affinity that correlates well with their functional potencies. SQ 27,986, PDG2 and SQ 28,852 show marginal affinity, indicating that their biological actions are not mediated via the TXA2 receptor.
一系列7-氧杂双环[2.2.1]庚酸的微小结构变化产生了四种可改变血栓素A2(TXA2)和前列腺素(PG)作用的药物。我们发现SQ 26,655是一种TXA2受体激动剂,SQ 28,668和SQ 29,548是TXA2受体拮抗剂,SQ 28,852是一种环氧化酶(CO)抑制剂,而SQ 27,986是一种前列环素(PGI2)/前列腺素D2(PGD2)激动剂。SQ 30,077以高亲和力与人类血小板膜中的一个位点可逆结合。SQ 30,077的特异性结合受到已鉴定的TXA2受体激动剂和拮抗剂的竞争性抑制,其亲和力顺序与其功能效力密切相关。SQ 27,986、前列腺素D2(PDG2)和SQ 28,852显示出微弱的亲和力,表明它们的生物学作用不是通过TXA2受体介导的。